[go: up one dir, main page]

WO2006115509A3 - Small molecule immunopotentiators and assays for their detection - Google Patents

Small molecule immunopotentiators and assays for their detection Download PDF

Info

Publication number
WO2006115509A3
WO2006115509A3 PCT/US2005/022520 US2005022520W WO2006115509A3 WO 2006115509 A3 WO2006115509 A3 WO 2006115509A3 US 2005022520 W US2005022520 W US 2005022520W WO 2006115509 A3 WO2006115509 A3 WO 2006115509A3
Authority
WO
WIPO (PCT)
Prior art keywords
methods
small molecule
smip
assays
detection
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2005/022520
Other languages
French (fr)
Other versions
WO2006115509A2 (en
Inventor
Nicholas Valiante
Feng Xu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis Vaccines and Diagnostics Inc
Original Assignee
Novartis Vaccines and Diagnostics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Vaccines and Diagnostics Inc filed Critical Novartis Vaccines and Diagnostics Inc
Priority to JP2007518321A priority Critical patent/JP2008504286A/en
Priority to US11/630,550 priority patent/US20110104186A1/en
Priority to EP05857800A priority patent/EP1768662A2/en
Priority to CA002571710A priority patent/CA2571710A1/en
Publication of WO2006115509A2 publication Critical patent/WO2006115509A2/en
Anticipated expiration legal-status Critical
Publication of WO2006115509A3 publication Critical patent/WO2006115509A3/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4706—4-Aminoquinolines; 8-Aminoquinolines, e.g. chloroquine, primaquine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The invention provides immunostimulatory compositions comprising a small molecule immuno-potentiator (SMIP) compound and methods of administration thereof. Also provided are methods of administering a SMIP compound in an effective amount to enhance the immune response of a subject to an antigen. Further provided are novel compositions and methods of administering SMIP compounds alone or in combination with another agent for the treatment of cancer, infectious diseases and/or allergies/asthma. In a further aspect, the invention relates generally to methods of screening for small molecule immuno-modulatory compositions.
PCT/US2005/022520 2004-06-24 2005-06-24 Small molecule immunopotentiators and assays for their detection Ceased WO2006115509A2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
JP2007518321A JP2008504286A (en) 2004-06-24 2005-06-24 Small molecule immune potentiators and assays for their detection
US11/630,550 US20110104186A1 (en) 2004-06-24 2005-06-24 Small molecule immunopotentiators and assays for their detection
EP05857800A EP1768662A2 (en) 2004-06-24 2005-06-24 Small molecule immunopotentiators and assays for their detection
CA002571710A CA2571710A1 (en) 2004-06-24 2005-06-24 Small molecule immunopotentiators and assays for their detection

Applications Claiming Priority (18)

Application Number Priority Date Filing Date Title
US58265404P 2004-06-24 2004-06-24
US60/582,654 2004-06-24
US59045904P 2004-07-22 2004-07-22
US60/590,459 2004-07-22
US59959204P 2004-08-05 2004-08-05
US59971704P 2004-08-05 2004-08-05
US60/599,592 2004-08-05
US60/599,717 2004-08-05
US60085004P 2004-08-11 2004-08-11
US60/600,850 2004-08-11
US60300104P 2004-08-19 2004-08-19
US60/603,001 2004-08-19
US60386704P 2004-08-23 2004-08-23
US60/603,867 2004-08-23
US61207004P 2004-09-21 2004-09-21
US60/612,070 2004-09-21
US61496304P 2004-09-30 2004-09-30
US60/614,963 2004-09-30

Publications (2)

Publication Number Publication Date
WO2006115509A2 WO2006115509A2 (en) 2006-11-02
WO2006115509A3 true WO2006115509A3 (en) 2007-08-16

Family

ID=37027454

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2005/022520 Ceased WO2006115509A2 (en) 2004-06-24 2005-06-24 Small molecule immunopotentiators and assays for their detection

Country Status (4)

Country Link
US (1) US20110104186A1 (en)
EP (2) EP1768662A2 (en)
CA (1) CA2571710A1 (en)
WO (1) WO2006115509A2 (en)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014022728A1 (en) 2012-08-02 2014-02-06 Endo Pharmaceuticals, Inc Substituted 5 - (quinazolin - 2 - yl) pyrimidin- 2 -amine derivatives useful as pi3k/mtor inhibitors for the treatment of cancer
WO2014028909A1 (en) * 2012-08-16 2014-02-20 Ohio State Innovation Foundation Stat3 inhibitors and their anticancer use
CA2882579A1 (en) 2012-08-21 2014-02-27 Cornell University Inhibitors of crl4 ubiquitin ligase and uses thereof
EP2953628B1 (en) 2013-02-11 2018-10-10 Glycanova AS Basidiomycete-derived cream for treatment of skin diseases
US10130609B2 (en) 2013-03-13 2018-11-20 University Health Network Pyrazole derivatives and their uses thereof
CN106132422A (en) 2014-02-27 2016-11-16 莱斯拉公司 Adoptive cell therapy & related treatments using agonists of retinoic acid receptor-related orphan receptor gamma
US9896441B2 (en) 2014-05-05 2018-02-20 Lycera Corporation Tetrahydroquinoline sulfonamide and related compounds for use as agonists of RORγ and the treatment of disease
WO2015171558A2 (en) 2014-05-05 2015-11-12 Lycera Corporation BENZENESULFONAMIDO AND RELATED COMPOUNDS FOR USE AS AGONISTS OF RORγ AND THE TREATEMENT OF DISEASE
CA2982847A1 (en) 2015-05-05 2016-11-10 Lycera Corporation Dihydro-2h-benzo[b][1,4]oxazine sulfonamide and related compounds for use as agonists of ror.gamma. and the treatment of disease
JP6838004B2 (en) 2015-06-11 2021-03-03 リセラ・コーポレイションＬｙｃｅｒａ Ｃｏｒｐｏｒａｔｉｏｎ Aryldihydro-2H-benzo [b] [1,4] oxazine sulfonamides and related compounds for use as agonists of RORγ and for the treatment of diseases
US10940125B2 (en) 2015-09-18 2021-03-09 Duke University Methods and compositions for the treatment of steatosis-associated disorders
CN116854686A (en) 2017-05-19 2023-10-10 智优有限公司 Derivatives of resiquimod
CN110632207B (en) * 2019-10-10 2022-04-29 南京财经大学 A method for identifying molds based on volatile gas components and their evolution trends
EP4149443A4 (en) * 2020-05-11 2024-05-29 Revir, Inc. Compositions and methods for treating viral infections
US10973908B1 (en) 2020-05-14 2021-04-13 David Gordon Bermudes Expression of SARS-CoV-2 spike protein receptor binding domain in attenuated salmonella as a vaccine
MX2022015290A (en) * 2020-06-03 2023-03-06 Ishihara Sangyo Kaisha Antimicrobial agent for nonhuman animal.

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4017608A (en) * 1973-12-14 1977-04-12 Strategic Medical Research Corporation Therapeutic composition and method of therapeutically treating warm blooded animals therewith
JP2004155777A (en) * 2002-10-16 2004-06-03 Asahi Kasei Pharma Kk Therapeutic agent for chronic hepatitis c
US20050037018A1 (en) * 2003-06-20 2005-02-17 Innogentics N.V. HCV combination therapy

Family Cites Families (495)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SU548947A1 (en) 1975-09-05 1980-02-05 Всесоюзный Ордена Ленина Институт Экспериментальной Ветеринарии Васхнил Vaccine for specific prophylaxis and therapy of horse trichophytosis
NO153458C (en) 1978-06-07 1986-03-26 Inst Experimentalnoi Veterinar PROCEDURE FOR THE PREPARATION OF PROPHYLAXY VACCINE AND TREATMENT OF RING WORM OF FUR ANIMALS AND Rabbits CAUSED BY TRICHOPHYTON MENTAGROPHYTES.
DE2854439A1 (en) 1978-12-16 1980-07-03 Hoechst Ag AN ISOXAZOLE DERIVATIVE, METHOD FOR THE PRODUCTION THEREOF, AGENT AND USE THEREOF
US4314061A (en) 1979-10-31 1982-02-02 Murdock Keith C Certain 3,6-bis-(heteroaminoalkoxy) acridines
US4347315A (en) 1980-04-25 1982-08-31 Burroughs Wellcome Co. Synthesis of ribosides using bacterial phosphorylase
IE52670B1 (en) 1981-03-03 1988-01-20 Leo Ab Heterocyclic carboxamides,compositions containing such compounds,and processes for their preparation
US5360897A (en) 1981-08-31 1994-11-01 The University Of Rochester Immunogenic conjugates of streptococcus pneumonial capsular polymer and toxin or in toxiad
ES8407097A1 (en) 1982-05-12 1984-08-16 Harvard College A PROCEDURE FOR OBTAINING A HYBRID PROTEIN.
US4525299A (en) 1983-05-10 1985-06-25 Zaidan Hojin Biseibutsu Kagaku Kenkyu Kai (-)-15-Deoxyspergualin, process for the preparation thereof, and intermediate of the same
DE3329186A1 (en) 1983-08-12 1985-02-21 Hoechst Ag, 6230 Frankfurt CHROMONAL CALALIDE, METHOD FOR ITS INSULATION FROM DYSOXYLUM BINECTARIFERUM, AND ITS USE AS A MEDICINAL PRODUCT
IL73534A (en) 1983-11-18 1990-12-23 Riker Laboratories Inc 1h-imidazo(4,5-c)quinoline-4-amines,their preparation and pharmaceutical compositions containing certain such compounds
US4894366A (en) 1984-12-03 1990-01-16 Fujisawa Pharmaceutical Company, Ltd. Tricyclo compounds, a process for their production and a pharmaceutical composition containing the same
FR2564831B3 (en) 1984-05-25 1986-09-05 Rolland Sa A NOVEL DERIVATIVES OF AROYL- OR HYDROAROYL N-ALCOYL PYRROLYL-2 CARBOXYLIC ACIDS AND NEW IMMUNO-SUPPRESSIVE PHARMACEUTICAL COMPOSITIONS
US4648996A (en) 1984-07-27 1987-03-10 Hoffmann-La Roche Inc. Phenyl substituted-2,4,6,8-nonatetraenoic acid
US5266692A (en) 1984-12-03 1993-11-30 Fujisawa Pharmaceutical Co., Ltd. Tricyclo compounds, a process for their production and a pharmaceutical composition containing the same
US5254562A (en) 1984-12-03 1993-10-19 Fujisawa Pharmaceutical Company, Ltd. Tricyclo compounds, a process for their production and a pharmaceutical composition containing the same
FR2599039B1 (en) 1986-05-22 1988-08-05 Rhone Poulenc Sante NEW IMMUNO-SUPPRESSIVE SUBSTANCE, ITS PREPARATION BY CULTURE OF STREPTOMYCES SP. (CBS 162.86) AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING IT
US5268382A (en) 1985-09-27 1993-12-07 Hoechst Aktiengesellschaft Medicaments to combat autoimmune diseases, in particular systemic lupus erythematosus
DE3534440A1 (en) 1985-09-27 1987-04-02 Hoechst Ag DRUGS AGAINST CHRONIC GRAFT VERSUS HOST DISEASES AND AUTO AUTO DISEASES, IN PARTICULAR SYSTEMIC LUPUS ERYTHEMATODES
GB8608080D0 (en) 1986-04-02 1986-05-08 Fujisawa Pharmaceutical Co Solid dispersion composition
US4806352A (en) 1986-04-15 1989-02-21 Ribi Immunochem Research Inc. Immunological lipid emulsion adjuvant
DE268678T1 (en) 1986-05-30 1988-11-24 Fuji Kagaku Kogyo K.K., Toyama NEW 5-FLUORURIDINE COMPOUNDS AND THEIR PRODUCTION.
DE3788902T3 (en) 1986-06-17 2004-11-25 Chiron Corp. (N.D.Ges.D. Staates Delaware), Emeryville Hepatitis delta diagnostics and vaccines, their manufacture and use.
DE3626306A1 (en) 1986-08-02 1988-02-11 Behringwerke Ag USE OF 15-DEOXYSPERGUALIN AS A MEDICINAL PRODUCT
ES2037072T3 (en) 1986-12-19 1993-06-16 Duphar International Research B.V STABILIZED COADJUVANT SUSPENSION INCLUDING DIMETHYL-DIOCTADECIL-AMMONIUM BROMIDE.
WO1988005783A1 (en) 1987-01-28 1988-08-11 Ortho Pharmaceutical Corporation Immunosuppressive peptides and methods of use
US5888512A (en) 1987-01-30 1999-03-30 Board Of Trustees Of The Leland Stanford Junior University Lymphocyte activity regulation by HLA peptides
WO1988005784A1 (en) 1987-01-30 1988-08-11 The Board Of Trustees Of The Leland Stanford Junio Lymphocyte inhibition by hla peptides
DE3702755A1 (en) 1987-01-30 1988-08-11 Hoechst Ag 3,5-DI-TERT.-BUTYL-4-HYDROXYBENZOESAEUREAMID, MISCELLANEOUS OF THE DERIVATIVES THEREOF, METHOD FOR PRODUCING THESE COMPOUNDS, THE MEDICINAL PRODUCTS CONTAINING THEM AND THEIR USE
US4753935A (en) 1987-01-30 1988-06-28 Syntex (U.S.A.) Inc. Morpholinoethylesters of mycophenolic acid and pharmaceutical compositions
ES2052685T3 (en) 1987-03-17 1994-07-16 Akzo Nv METHOD TO PRODUCE A FREE ADJUVANT.
US4925920A (en) 1987-05-29 1990-05-15 Brigham And Women's Hospital Immunosuppressive polypeptides
US4885276A (en) 1987-06-03 1989-12-05 Merck & Co., Inc. Cyclosporin analogs with modified "C-9 amino acids"
US5227467A (en) 1987-08-03 1993-07-13 Merck & Co., Inc. Immunosuppressive fluorinated cyclosporin analogs
JPH0670025B2 (en) 1987-08-07 1994-09-07 鐘紡株式会社 Benzothiazole derivative and antirheumatic agent containing the compound as an active ingredient
US4963557A (en) 1987-09-28 1990-10-16 Smithkline Beecham Corporation Immunomodulatory azaspiranes
WO1989003385A1 (en) 1987-10-13 1989-04-20 Yoshitomi Pharmaceutical Industries, Ltd. Fused pyrazole compounds, process for their preparation, and their medicinal use
GB8728820D0 (en) 1987-12-09 1988-01-27 Fisons Plc Compounds
US5087619A (en) 1988-01-20 1992-02-11 Hoffman-La Roche Inc. Vitamin D3 analogs
US5087703A (en) 1988-01-28 1992-02-11 Merck & Co., Inc. Process for synthesis of FK-506 intermediates
WO1989006968A1 (en) 1988-02-03 1989-08-10 Xoma Corporation Therapeutic use of anti-t cell immunotoxin for autoimmune diseases
US5049659A (en) 1988-02-09 1991-09-17 Dana Farber Cancer Institute Proteins which induce immunological effector cell activation and chemattraction
EP0364598A4 (en) 1988-03-02 1992-01-15 Yoshitomi Pharmaceutical Industries, Ltd. 3,4-dihydrothieno 2,3-d¨pyrimidine compounds and pharmaceutical application thereof
CA1339964C (en) 1988-03-16 1998-07-21 Dennis A. Carson Substituted adenine derivatives useful as therapeutic agents
US5173499A (en) 1988-04-15 1992-12-22 T Cell Sciences, Inc. Compounds which inhibit complement and/or suppress immune activity
US5366986A (en) 1988-04-15 1994-11-22 T Cell Sciences, Inc. Compounds which inhibit complement and/or suppress immune activity
EP0338168A1 (en) 1988-04-19 1989-10-25 Merrell Dow Pharmaceuticals Inc. Phosphonoalkylpurine derivatives
US4895872A (en) 1989-03-15 1990-01-23 Cetus Corporation Immunosupressive analogues and derivatives of succinylacetone
US4981792A (en) 1988-06-29 1991-01-01 Merck & Co., Inc. Immunosuppressant compound
US4894374A (en) 1988-08-17 1990-01-16 American Home Products Corporation Substituted 1,2-dihydro-4h-3,1-benzoxazin-4-one derivatives inhibitors of interleukin 1
US5219884A (en) 1988-09-14 1993-06-15 Taito Co., Ltd. Immunosuppressant
JPH02101065A (en) 1988-10-06 1990-04-12 Tanabe Seiyaku Co Ltd Imidazoline derivatives and their production method
DE3841091A1 (en) 1988-12-07 1990-06-13 Behringwerke Ag SYNTHETIC ANTIGENS, METHOD FOR THEIR PRODUCTION AND THEIR USE
US5238944A (en) 1988-12-15 1993-08-24 Riker Laboratories, Inc. Topical formulations and transdermal delivery systems containing 1-isobutyl-1H-imidazo[4,5-c]quinolin-4-amine
SE8804640L (en) 1988-12-23 1990-06-24 Ferring Ab MEDICINAL COMPREHENSIVE CYCLOLINOPEPTIDE A
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
FR2641537A1 (en) 1989-01-09 1990-07-13 Centre Nat Rech Scient OXYSTERYL PHOSPHATES, SYNTHESIS AND USE AS A PHARMACEUTICAL AGENT
US4975372A (en) 1989-01-13 1990-12-04 Merck & Co., Inc. Microbial transformation product of L-683,590
CA2006700A1 (en) 1989-01-17 1990-07-17 Antonello Pessi Synthetic peptides and their use as universal carriers for the preparation of immunogenic conjugates suitable for the development of synthetic vaccines
US4968702A (en) 1989-01-17 1990-11-06 American Cyanamid Company Substituted quinolinecarboxylic acids
RU2093513C1 (en) 1989-02-27 1997-10-20 Биокрайст Фармасьютикалз Инк. 9-deazaguanine derivatives or their tautomers and pharmaceutical composition showing capability to inhibit mammal purine nucleoside phosphorylase activity
US4929624A (en) 1989-03-23 1990-05-29 Minnesota Mining And Manufacturing Company Olefinic 1H-imidazo(4,5-c)quinolin-4-amines
US4940797A (en) 1989-03-23 1990-07-10 Merck & Co., Inc. Process for synthesis of FK-506 C10-C18 intermediates
CA2011896C (en) 1989-04-21 2001-05-08 Mark Werner Ringworm vaccine
US4987139A (en) 1989-05-05 1991-01-22 Merck & Co., Inc. FK-520 microbial transformation product
WO1990014357A1 (en) 1989-05-19 1990-11-29 Genentech, Inc. Her2 extracellular domain
US5061786A (en) 1989-05-25 1991-10-29 Genentech, Inc. Biologically active polypeptides based on transforming growth factor-β
WO1990014837A1 (en) 1989-05-25 1990-12-13 Chiron Corporation Adjuvant formulation comprising a submicron oil droplet emulsion
IE64214B1 (en) 1989-06-06 1995-07-26 Fujisawa Pharmaceutical Co Macrolides for the treatment of reversible obstructive airways diseases
NZ234674A (en) 1989-08-02 1992-02-25 Seragen Inc Mutant interleukin-2,dna encoding it, host cells, cytotoxic and toxin-mutant il-2 conjugates
DK0444181T3 (en) 1989-08-04 2002-02-25 Schering Ag C-erbB-2 External Domain: gp75
US4939168A (en) 1989-08-11 1990-07-03 Harbor Branch Oceanographics Institution, Inc. Discodermolide compounds, compositions containing same and methods of preparation and use
WO1991002736A1 (en) 1989-08-18 1991-03-07 Fisons Plc Macrocyclic compounds
US5011943A (en) 1989-08-28 1991-04-30 Merck Frosst Canada, Inc. FK-506 C10 -C24 process intermediates
IT1237764B (en) 1989-11-10 1993-06-17 Eniricerche Spa SYNTHETIC PEPTIDES USEFUL AS UNIVERSAL CARRIERS FOR THE PREPARATION OF IMMUNOGENIC CONJUGATES AND THEIR USE FOR THE DEVELOPMENT OF SYNTHETIC VACCINES.
US5189039A (en) 1989-11-29 1993-02-23 Biocryst, Inc. 7-disubstituted-methyl-4-oxo-3H,5H-pyrrolo[3,2d]pyrimidine and pharmaceutical uses and compositions containing the same
GB9000301D0 (en) 1990-01-06 1990-03-07 Pfizer Ltd Piperidine & pyrrolidine derivatives
US5001124A (en) 1990-02-02 1991-03-19 Syntex (U.S.A.) Inc. 4-isoxazolecarboxamide derivatives
US5196437A (en) 1990-02-13 1993-03-23 Fujisawa Pharmaceutical Company, Ltd. Method for treating hepatic diseases and regenerating liver tissue using FK 506 and related compounds
US5064835A (en) 1990-03-01 1991-11-12 Merck & Co., Inc. Hydroxymacrolide derivatives having immunosuppressive activity
JPH05504956A (en) 1990-03-12 1993-07-29 藤沢薬品工業株式会社 tricyclo compound
JPH05505798A (en) 1990-03-13 1993-08-26 フアイソンズ・ピーエルシー Immunosuppressive macrocyclic compounds
EP0528858B1 (en) 1990-04-14 1997-01-22 New England Medical Center Hospitals, Inc. Inhibitors of dipeptidyl-aminopeptidase type iv
WO1991017754A1 (en) 1990-05-11 1991-11-28 Fujisawa Pharmaceutical Co., Ltd. Methods for treating and preventing inflammation of mucosa and blood vessels using fk 506 and related compounds
RU2142937C1 (en) 1990-05-18 1999-12-20 Хехст АГ Amides of organic acids, method of their synthesis and pharmaceutical composition
FI920480A0 (en) 1990-06-05 1992-02-04 Toray Industries INDOLDERIVAT.
JPH05507915A (en) 1990-06-11 1993-11-11 藤沢薬品工業株式会社 Application of macrolide compounds such as FK506 for the production of therapeutic agents for idiopathic thrombocytopenic purpura and Graves' disease
GB9014136D0 (en) 1990-06-25 1990-08-15 Fujisawa Pharmaceutical Co Tricyclo compounds,a process for their production and a pharmaceutical composition containing the same
US5260323A (en) 1990-06-28 1993-11-09 Hoechst Aktiengesellschaft 2,4- and 2,5-substituted pyridine-N-oxides, processes for their preparation and their use
GB9014681D0 (en) 1990-07-02 1990-08-22 Fujisawa Pharmaceutical Co Tricyclo compounds,a process for their production and a pharmaceutical composition containing the same
US5192773A (en) 1990-07-02 1993-03-09 Vertex Pharmaceuticals, Inc. Immunosuppressive compounds
GB9014881D0 (en) 1990-07-05 1990-08-22 Fujisawa Pharmaceutical Co Tricyclo compounds,a process for their production and a pharmaceutical composition containing the same
US5023264A (en) 1990-07-16 1991-06-11 American Home Products Corporation Rapamycin oximes
US5120726A (en) 1991-03-08 1992-06-09 American Home Products Corporation Rapamycin hydrazones
US5023263A (en) 1990-08-09 1991-06-11 American Home Products Corporation 42-oxorapamycin
WO1992002229A1 (en) 1990-08-10 1992-02-20 Smithkline Beecham Corporation Immunosuppressive compositions
DE69113564T2 (en) 1990-08-13 1996-05-30 American Cyanamid Co Bordetella pertussis fiber hemagglutinin as a carrier for conjugated vaccine.
US5384316A (en) 1990-08-18 1995-01-24 Fisons Plc 4,16-diazatetracyclo[23.3.1.1.Hu 14,17=b . 0 Hu 4,9 triaconta-16,19-diene-2,3,10-trione derivatives
US5130307A (en) 1990-09-28 1992-07-14 American Home Products Corporation Aminoesters of rapamycin
PT98990A (en) 1990-09-19 1992-08-31 American Home Prod PROCESS FOR THE PREPARATION OF CARBOXYLIC ACID ESTERS OF RAPAMICIN
SE467410B (en) 1990-09-25 1992-07-13 Ferring Ab ANALOGS OF CYCLOLINOPEPTIDE AND USE THEREOF
GB9020931D0 (en) 1990-09-26 1990-11-07 Wellcome Found Heterocyclic compounds
US5153312A (en) 1990-09-28 1992-10-06 American Cyanamid Company Oligosaccharide conjugate vaccines
US5143918A (en) 1990-10-11 1992-09-01 Merck & Co., Inc. Halomacrolides and derivatives having immunosuppressive activity
US5233036A (en) 1990-10-16 1993-08-03 American Home Products Corporation Rapamycin alkoxyesters
US5277904A (en) 1990-10-26 1994-01-11 Pier Allan C Broad spectrum dermatophyte vaccine
US5284652A (en) 1990-10-26 1994-02-08 Pier Allan C Dermatophyte vaccine
CH682809A5 (en) 1990-12-12 1993-11-30 Buehler Ag Automatic product feed system, method for controlling the grinding of a Müllereiwalzenstuhles.
US5247119A (en) 1990-12-12 1993-09-21 G. D. Searle & Co. Phenylacetonitrilehydroxyalkylaminoalkyl-ortho-substituted aryl compounds as immunosuppressives
GB9027471D0 (en) 1990-12-19 1991-02-06 Fujisawa Pharmaceutical Co Novel compound
JP3159705B2 (en) 1990-12-21 2001-04-23 キュラティブ テクノロジーズ，インコーポレーテッド Angiogenic peptide
WO1992013874A2 (en) 1991-01-02 1992-08-20 Fox Chase Cancer Center Angiogenic peptides
US5194378A (en) 1991-01-28 1993-03-16 Merck & Co., Inc. Process for producing fk-506
US5679640A (en) 1991-02-12 1997-10-21 Cytel Corporation Immunosuppressant peptides
US5078999A (en) 1991-02-22 1992-01-07 American Home Products Corporation Method of treating systemic lupus erythematosus
US5080899A (en) 1991-02-22 1992-01-14 American Home Products Corporation Method of treating pulmonary inflammation
US5389640A (en) 1991-03-01 1995-02-14 Minnesota Mining And Manufacturing Company 1-substituted, 2-substituted 1H-imidazo[4,5-c]quinolin-4-amines
US5219864A (en) 1991-03-12 1993-06-15 Kyowa Hakko Kogyo Co., Ltd. Thienopyridine derivatives
US5120842A (en) 1991-04-01 1992-06-09 American Home Products Corporation Silyl ethers of rapamycin
US5321009A (en) 1991-04-03 1994-06-14 American Home Products Corporation Method of treating diabetes
US5100883A (en) 1991-04-08 1992-03-31 American Home Products Corporation Fluorinated esters of rapamycin
US5091381A (en) 1991-04-12 1992-02-25 Biomeasure, Inc. 2H-1,3,4-benzotriazepin-2-ones
US5118678A (en) 1991-04-17 1992-06-02 American Home Products Corporation Carbamates of rapamycin
JP3204972B2 (en) 1991-04-17 2001-09-04 グリューネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング Novel thalidomide derivative, method for producing the same, and method of using the same as drug
US5194447A (en) 1992-02-18 1993-03-16 American Home Products Corporation Sulfonylcarbamates of rapamycin
US5147877A (en) 1991-04-18 1992-09-15 Merck & Co. Inc. Semi-synthetic immunosuppressive macrolides
US5093338A (en) 1991-04-23 1992-03-03 Merck & Co., Inc. Lipophilic macrolide useful as an immunosuppressant
US5091389A (en) 1991-04-23 1992-02-25 Merck & Co., Inc. Lipophilic macrolide useful as an immunosuppressant
US5183906A (en) 1991-04-30 1993-02-02 Allergan, Inc. 2- and 5-alkyl and phenyl substituted 4-(1-hydroxy, 1-acyloxy or 1-carbamoyloxy)-5-hydroxy-2 (5h)-furanones as anti-inflammatory agents
US5225571A (en) 1991-04-30 1993-07-06 Allergan, Inc. Substituted dihydroxy-bis-[5-hydroxy-2(5H)-furanone-4-yl]-alkanes as anti-inflammatory agents
US5102876A (en) 1991-05-07 1992-04-07 American Home Products Corporation Reduction products of rapamycin
US5162334A (en) 1991-05-13 1992-11-10 Merck & Co., Inc. Amino O-alkyl, O-alkenyl and O-alkynlmacrolides having immunosuppressive activity
US5262533A (en) 1991-05-13 1993-11-16 Merck & Co., Inc. Amino O-aryl macrolides having immunosuppressive activity
US5565560A (en) 1991-05-13 1996-10-15 Merck & Co., Inc. O-Aryl,O-alkyl,O-alkenyl and O-alkynylmacrolides having immunosuppressive activity
WO1992020688A1 (en) 1991-05-13 1992-11-26 Merck & Co., Inc. Amino o-aryl, o-alkyl, o-alkenyl and o-alkynyl macrolides
US5776943A (en) 1991-05-14 1998-07-07 American Home Products Corporation Rapamycin metabolites
US5118677A (en) 1991-05-20 1992-06-02 American Home Products Corporation Amide esters of rapamycin
MX9202466A (en) 1991-05-24 1994-06-30 Vertex Pharma NOVELTY IMMUNOSUPPRESSIVE COMPOUNDS.
US5120727A (en) 1991-05-29 1992-06-09 American Home Products Corporation Rapamycin dimers
US5120725A (en) 1991-05-29 1992-06-09 American Home Products Corporation Bicyclic rapamycins
PT100566B (en) 1991-06-07 1999-06-30 Smithkline Beecham Corp IMMUNOMODULATOR AZASPIRANES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, PREPARATION AND USE
IL102414A (en) 1991-07-25 1996-08-04 Univ Louisville Res Found Pharmaceutical compositions for treating ocular inflammation comprising rapamycin
GB9116241D0 (en) 1991-07-27 1991-09-11 Boots Co Plc Therapeutic agents
US5149701A (en) 1991-08-01 1992-09-22 Merck & Co., Inc. C-31 methylated FR-900520 cyclic hemiketal immunosuppressant agents
US5189042A (en) 1991-08-22 1993-02-23 Merck & Co. Inc. Fluoromacrolides having immunosuppressive activity
US5169963A (en) 1991-08-30 1992-12-08 Allergan, Inc. Di-(5-hydroxy-2(5H)2-oxo-4-furyl)alkylmethyl-alpha,omega alkanedioates and N,N-bis-(5-hydroxy-2(5H)2-oxo-4-furyl)alkylmethyl-alpha,omega-dialkanoic acid amides as anti-inflammatory agents
US5171864A (en) 1991-08-30 1992-12-15 Allergan, Inc. Di-(5-hydroxy-2(5H)-2-oxo-4-furyl)methyl-alpha,omega alkane-dioates and N,N-bis-(5-hydroxy-2(5H)-2-oxo-4-furyl)methyl-alpha,omega-dialkanoic acid amides as anti-inflammatory agents
US5268376A (en) 1991-09-04 1993-12-07 Minnesota Mining And Manufacturing Company 1-substituted 1H-imidazo[4,5-c]quinolin-4-amines
US5604234A (en) 1991-09-05 1997-02-18 Abbott Laboratories Substituted thiol macrolactam immunomodulators
JPH06510304A (en) 1991-09-05 1994-11-17 アボツト・ラボラトリーズ macrocyclic immunomodulator
US5252732A (en) 1991-09-09 1993-10-12 Merck & Co., Inc. D-heteroaryl, O-alkylheteroaryl, O-alkenylheteroaryl and O-alkynylheteroarylmacrolides having immunosuppressive activity
US5247076A (en) 1991-09-09 1993-09-21 Merck & Co., Inc. Imidazolidyl macrolides having immunosuppressive activity
US5208241A (en) 1991-09-09 1993-05-04 Merck & Co., Inc. N-heteroaryl, n-alkylheteroaryl, n-alkenylheteroaryl and n-alkynylheteroarylmacrolides having immunosuppressive activity
US5356897A (en) 1991-09-09 1994-10-18 Fujisawa Pharmaceutical Co., Ltd. 3-(heteroaryl)-pyrazololi[1,5-a]pyrimidines
US5162333A (en) 1991-09-11 1992-11-10 American Home Products Corporation Aminodiesters of rapamycin
US5286730A (en) 1991-09-17 1994-02-15 American Home Products Corporation Method of treating immunoinflammatory disease
GB9122721D0 (en) 1991-10-25 1991-12-11 Smithkline Beecham Corp Methods
WO1993008802A1 (en) 1991-10-31 1993-05-13 Fujisawa Pharmaceutical Co., Ltd. Liposome preparation containing tricyclic compound
US5266575A (en) 1991-11-06 1993-11-30 Minnesota Mining And Manufacturing Company 2-ethyl 1H-imidazo[4,5-ciquinolin-4-amines
US5164399A (en) 1991-11-18 1992-11-17 American Home Products Corporation Rapamycin pyrazoles
US5326752A (en) 1991-11-27 1994-07-05 Glycomed Incorporated Substituted lactose and lactosamine derivatives as cell adhesion inhibitors
FI942503A0 (en) 1991-11-29 1994-05-27 Viagene Inc Immunotherapeutic anticancer vector constructs
GB9125660D0 (en) 1991-12-03 1992-01-29 Smithkline Beecham Plc Novel compound
GB9126870D0 (en) 1991-12-18 1992-02-19 Fujisawa Pharmaceutical Co Novel compound
US5360792A (en) * 1991-12-20 1994-11-01 Greenwich Pharmaceuticals Incorporated Anti-proliferative and anti-inflammatory compounds: 5- or 6-deoxy hexose monosaccharides having a saturated nitrogen-containing heterocycle at the 5- or 6-position bound through the nitrogen atom
US5221740A (en) 1992-01-16 1993-06-22 American Home Products Corporation Oxepane isomers of rapamycin useful as immunosuppressive agents
GB9202196D0 (en) 1992-02-01 1992-03-18 Fisons Plc Method of treatment
US5980954A (en) * 1992-02-07 1999-11-09 Vasogen Ireland Limited Treatment of autoimmune diseases
GB9203265D0 (en) 1992-02-15 1992-04-01 Fisons Plc Pharmaceutically active compound
CA2383007A1 (en) 1992-03-02 1993-09-16 Chiron S.P.A. Helicobacter pylori proteins useful for vaccines and diagnostics
WO1993018049A1 (en) 1992-03-02 1993-09-16 Pfizer Inc. Fluorosugar derivatives of macrolides
EP0636136B1 (en) 1992-03-02 1997-10-29 Pfizer Inc. 2-aminosugar derivatives of macrolides
DK0629203T3 (en) 1992-03-02 2001-11-12 Pfizer Desosamine derivatives of macrolides as immunosuppressants and antifungal agents
DE69310721T2 (en) 1992-03-02 1997-09-04 Pfizer SUGAR DERIVATIVES OF MACROLIDS
IT1262896B (en) 1992-03-06 1996-07-22 CONJUGATE COMPOUNDS FORMED FROM HEAT SHOCK PROTEIN (HSP) AND OLIGO-POLY-SACCHARIDES, THEIR USE FOR THE PRODUCTION OF VACCINES.
AU681579B2 (en) 1992-03-30 1997-09-04 Wyeth Rapamycin formulation for IV injection
DE69319859T2 (en) 1992-04-24 1998-12-17 Kyowa Hakko Kogyo K.K., Tokio/Tokyo NEW TETRACYCLIC COMPOUNDS
JPH05344899A (en) * 1992-06-11 1993-12-27 Kokuritsu Yobou Eisei Kenkyusho Production of coat protein of hepatitis c virus
US5284877A (en) 1992-06-12 1994-02-08 Merck & Co., Inc. Alkyl and alkenyl macrolides having immunosuppressive activity
US5284840A (en) 1992-06-12 1994-02-08 Merck & Co., Inc. Alkylidene macrolides having immunosuppressive activity
ZA935110B (en) 1992-07-17 1994-02-04 Smithkline Beecham Corp Rapamycin derivatives
ZA935112B (en) 1992-07-17 1994-02-08 Smithkline Beecham Corp Rapamycin derivatives
ZA935111B (en) 1992-07-17 1994-02-04 Smithkline Beecham Corp Rapamycin derivatives
US5360794A (en) 1992-08-03 1994-11-01 Medicarb Inc. Disubstituted and deoxy disubstituted derivatives of α-D-mannofuranosides and β-L-gulofuranosides having anti-inflammatory and anti-proliferative activity
US5256790A (en) 1992-08-13 1993-10-26 American Home Products Corporation 27-hydroxyrapamycin and derivatives thereof
MX9304868A (en) 1992-08-13 1994-05-31 American Home Prod 27-HYDROXYRAPAMICINE, DERIVED FROM THE SAME AND PHARMACEUTICAL COMPOSITION THAT CONTAINS IT.
GB9218797D0 (en) 1992-09-04 1992-10-21 Fisons Plc Pharmacologically active compounds
GB9221220D0 (en) 1992-10-09 1992-11-25 Sandoz Ag Organic componds
WO1994008589A1 (en) 1992-10-09 1994-04-28 The Board Of Trustees Of The Leland Stanford Junior University Treatment of systemic lupus erythematosus with dehydroepiandrosterone
US5302584A (en) 1992-10-13 1994-04-12 American Home Products Corporation Carbamates of rapamycin
DK0627406T3 (en) 1992-10-21 1999-07-12 Taito Co 2-Amino-1,3-propanediol compounds and immunosuppressants
US5262423A (en) 1992-10-29 1993-11-16 American Home Products Corporation Rapamycin arylcarbonyl and alkoxycarbonyl carbamates as immunosuppressive and antifungal agents
US5258389A (en) 1992-11-09 1993-11-02 Merck & Co., Inc. O-aryl, O-alkyl, O-alkenyl and O-alkynylrapamycin derivatives
US5260300A (en) 1992-11-19 1993-11-09 American Home Products Corporation Rapamycin carbonate esters as immuno-suppressant agents
US5359073A (en) 1992-11-24 1994-10-25 G. D. Searle & Co. Substituted-phenyl (N,N'-cycloalkyl/alkyl carboxamide)-1H/3H-imidazo[4,5-b]pyridine compounds as PAF antagonists
WO1994012184A1 (en) 1992-11-24 1994-06-09 Syntex (U.S.A.) Inc. Use of mycophenolic acid, mycophenolate mofetil or derivate thereof to inhibit stenosis
SE9300012D0 (en) 1993-01-05 1993-01-05 Astra Ab NEW PEPTIDES
GB9300083D0 (en) 1993-01-05 1993-03-03 Roussel Lab Ltd Chemical compounds
US5395937A (en) 1993-01-29 1995-03-07 Minnesota Mining And Manufacturing Company Process for preparing quinoline amines
GB9302569D0 (en) 1993-02-10 1993-03-24 Smithkline Beecham Plc Novel compound
GB9302567D0 (en) 1993-02-10 1993-03-24 Smithkline Beecham Plc Novel compound
US5252579A (en) 1993-02-16 1993-10-12 American Home Products Corporation Macrocyclic immunomodulators
JP3525221B2 (en) 1993-02-17 2004-05-10 味の素株式会社 Immunosuppressants
CA2090171A1 (en) 1993-02-23 1994-08-24 Peter W. Schiller Opioid receptor antagonists, their synthesis and use as analgesic and immunosuppressive compounds
US5817311A (en) 1993-03-05 1998-10-06 Universite Catholique De Louvain Methods of inhibiting T-cell medicated immune responses with LO-CD2a-specific antibodies
US5310903A (en) 1993-03-05 1994-05-10 Merck & Co., Inc. Imidazolidyl rapamycin derivatives
US5730979A (en) 1993-03-05 1998-03-24 Universite Catholique Delouvain LO-CD2a antibody and uses thereof for inhibiting T cell activation and proliferation
US5468772A (en) 1993-03-10 1995-11-21 Pharmagenesis, Inc. Tripterinin compound and method
US5801005A (en) 1993-03-17 1998-09-01 University Of Washington Immune reactivity to HER-2/neu protein for diagnosis of malignancies in which the HER-2/neu oncogene is associated
US5869445A (en) 1993-03-17 1999-02-09 University Of Washington Methods for eliciting or enhancing reactivity to HER-2/neu protein
CA2159344A1 (en) 1993-03-30 1994-10-13 Minoru Moriwaki Cell adhesion inhibitor and thienotriazolodiazepine compound
TW314467B (en) 1993-03-31 1997-09-01 Hoechst Ag
IL109161A0 (en) 1993-03-31 1994-06-24 Cell Therapeutics Inc Amino alcohol derivatives, methods for the preparation thereof, and pharmaceutical compositions containing the same
US5837703A (en) 1993-03-31 1998-11-17 Cell Therapeutics, Inc. Amino-alcohol substituted cyclic compounds
GB9307491D0 (en) 1993-04-08 1993-06-02 Sandoz Ltd Organic compounds
AU6702894A (en) 1993-04-09 1994-11-08 Cell Therapeutics, Inc. Ring-substituted cell signaling inhibitors
WO1994024095A1 (en) 1993-04-16 1994-10-27 Abbott Laboratories Immunosuppressive agents
US5504091A (en) 1993-04-23 1996-04-02 American Home Products Corporation Biotin esters of rapamycin
US5759550A (en) 1993-05-06 1998-06-02 Pharmagenesis, Inc. Method for suppressing xenograft rejection
AU6826194A (en) 1993-05-06 1994-12-12 Pharmagenesis, Inc. 16-hydroxytriptolide composition and method for immunotherapy
US5455045A (en) 1993-05-13 1995-10-03 Syntex (U.S.A.) Inc. High dose formulations
GB9311562D0 (en) 1993-06-04 1993-07-21 Fujisawa Pharmaceutical Co Heterocyclic derivatives
US5352783A (en) 1993-06-09 1994-10-04 Merck & Co., Inc. Microbial transformation product having immunosuppressive activity
DE69432593T2 (en) 1993-06-11 2003-11-27 Boston Life Sciences, Inc. IMMUNOMODULATING, ANTI-INFLAMMATORY AND ANTIPROLIFERATIVE COMPOUNDS: 5,6-DIDEOXY, 5-AMINO DERIVATIVES OF IDOSE AND 6-DEOXY, 6-AMINO DERIVATIVES OF GLUCOSE
JP3645905B2 (en) 1993-06-18 2005-05-11 キュラティブ テクノロジーズ，インコーポレーテッド Anti-inflammatory peptide
WO1995001355A1 (en) 1993-06-30 1995-01-12 Biocryst Pharmaceuticals, Inc. 9-deazahypoxanthines as pnp inhibitors
EP0706393B1 (en) 1993-07-02 1999-09-08 The University Of Nottingham Immunosuppressant and antiallergic compounds, e.g. n-(3-oxohexanoyl) homoserine lactone
AU681687B2 (en) 1993-07-15 1997-09-04 Minnesota Mining And Manufacturing Company Imidazo(4,5-c)pyridin-4-amines
US5352784A (en) 1993-07-15 1994-10-04 Minnesota Mining And Manufacturing Company Fused cycloalkylimidazopyridines
US5451604A (en) 1993-07-26 1995-09-19 G. D. Searle & Co. Halogenated phenylacetonitrile alkylaminoalkylphenyl compounds as immunosuppressives
GB9315914D0 (en) 1993-07-31 1993-09-15 Smithkline Beecham Plc Novel compound
US5387680A (en) 1993-08-10 1995-02-07 American Home Products Corporation C-22 ring stabilized rapamycin derivatives
AU7508394A (en) 1993-08-25 1995-03-21 Taisho Pharmaceutical Co., Ltd. Alpha-pyrone compound
GB9318612D0 (en) 1993-09-08 1993-10-27 Sandoz Ltd An assay
HU217300B (en) 1993-09-15 1999-12-28 Syntex (U.S.A.) Inc. Crystalline anhydrous mycophenolate mofetil salts, intravenous formulations containing the compound and their preparation
GB9319534D0 (en) 1993-09-22 1993-11-10 Boots Co Plc Therapeutic agents
DE69430752T2 (en) 1993-09-28 2002-10-17 Kyowa Hakko Kogyo Co., Ltd. TETRACYCLIC COMPOUNDS
DK0721335T3 (en) 1993-10-01 2006-01-09 Roche Palo Alto Llc High dose oral suspensions of mycophenolate mofetil
US5373014A (en) 1993-10-08 1994-12-13 American Home Products Corporation Rapamycin oximes
US5378836A (en) 1993-10-08 1995-01-03 American Home Products Corporation Rapamycin oximes and hydrazones
US5391730A (en) 1993-10-08 1995-02-21 American Home Products Corporation Phosphorylcarbamates of rapamycin and oxime derivatives thereof
HUT74989A (en) 1993-11-12 1997-03-28 Merrell Pharma Inc 6-oxo-nucleosides useful as immunosuppressants
EP0729471A1 (en) 1993-11-19 1996-09-04 Abbott Laboratories Semisynthetic analogs of rapamycin (macrolides) being immunomodulators
US5385908A (en) 1993-11-22 1995-01-31 American Home Products Corporation Hindered esters of rapamycin
US5385909A (en) 1993-11-22 1995-01-31 American Home Products Corporation Heterocyclic esters of rapamycin
US5385910A (en) 1993-11-22 1995-01-31 American Home Products Corporation Gem-distributed esters of rapamycin
WO1995015328A1 (en) 1993-11-30 1995-06-08 Abbott Laboratories Macrocyclic immunomodulators with novel cyclohexyl ring replacements
IL111785A0 (en) 1993-12-03 1995-01-24 Ferring Bv Dp-iv inhibitors and pharmaceutical compositions containing them
US5461054A (en) 1993-12-09 1995-10-24 Bayer Aktiengesellschaft Anthracene-spiro-pyrrolindines
AU687491B2 (en) 1993-12-17 1998-02-26 Novartis Ag Rapamycin derivatives useful as immunosuppressants
GB9326284D0 (en) 1993-12-23 1994-02-23 Erba Carlo Spa Pyrrolydenemethyl-derivatives and process for their preparation
US5389639A (en) 1993-12-29 1995-02-14 American Home Products Company Amino alkanoic esters of rapamycin
US5610173A (en) 1994-01-07 1997-03-11 Sugen, Inc. Formulations for lipophilic compounds
US5700823A (en) 1994-01-07 1997-12-23 Sugen, Inc. Treatment of platelet derived growth factor related disorders such as cancers
AU1868195A (en) 1994-01-28 1995-08-15 Cell Therapeutics, Inc. Cell signaling inhibitors
US5550214A (en) 1994-02-10 1996-08-27 Brigham And Women's Hospital Isolated antigenic oncogene peptide fragments and uses
US5525602A (en) 1994-02-18 1996-06-11 Syntex (U.S.A.) Inc. Method of using 4-amino 6-substituted mycophenolic acid and derivatives
US5493030A (en) 1994-02-18 1996-02-20 Syntex (U.S.A.) Inc. 5-substituted derivatives of mycophenolic acid
US5444072A (en) 1994-02-18 1995-08-22 Syntex (U.S.A.) Inc. 6-substituted mycophenolic acid and derivatives
US5512568A (en) 1994-02-18 1996-04-30 Syntex (U.S.A.) Inc. Method of using 4-amino derivatives of 5-substituted mycophenolic acid
US5362735A (en) 1994-02-23 1994-11-08 Smithkline Beecham Corporation Rapamycin derivatives
US5523408A (en) 1994-03-25 1996-06-04 The Dupont Merck Pharmaceutical Company 2-carbocyclic and 2-heterocyclic quinoline-4-carboxylic acids and salts thereof useful as immunosuppressive agents
US5525610A (en) 1994-03-31 1996-06-11 American Home Products Corporation 42-Epi-rapamycin and pharmaceutical compositions thereof
US5451686A (en) 1994-04-15 1995-09-19 Allergan, Inc. 3 and 5 alkyl and phenyl 4-(hydroxy or acyloxy)-alkyl substituted 2(5H)-furanones as anti-inflammatory agents
US5362718A (en) 1994-04-18 1994-11-08 American Home Products Corporation Rapamycin hydroxyesters
IL109633A (en) 1994-05-11 2005-05-17 Yeda Res & Dev Tnf receptor promoter
SE9401728D0 (en) 1994-05-18 1994-05-18 Astra Ab New compounds II
US5463048A (en) 1994-06-14 1995-10-31 American Home Products Corporation Rapamycin amidino carbamates
US5880280A (en) 1994-06-15 1999-03-09 Merck & Co., Inc. Aryl, alkyl, alkenyl and alkynylmacrolides having immunosuppressive activity
WO1995035120A1 (en) 1994-06-17 1995-12-28 Alexion Pharmaceuticals, Inc. Monoclonal antibodies for the reduction of anti-xenogeneic immune responses
US5550233A (en) 1994-06-21 1996-08-27 Merck & Co., Inc. Aryl, alkyl, alkenyl and alkynylmacrolides having immunosuppressive activity
US5466697A (en) 1994-07-13 1995-11-14 Syntex (U.S.A.) Inc. 8-phenyl-1,6-naphthyridin-5-ones
GB9415161D0 (en) 1994-07-27 1994-09-14 Sandoz Ltd Organic compounds
PT778263E (en) 1994-08-22 2002-06-28 Mitsubishi Pharma Corp COMPOSITION OF BENZENE AND ITS PHARMACEUTICAL UTILIZATION
SE9402880D0 (en) 1994-08-30 1994-08-30 Astra Ab New peptide derivatives
HUT77436A (en) 1994-10-05 1998-04-28 Darwin Discovery Limited Purine and guanine derivatives, a process for their preparation, pharmaceutical compositions containing them and their use in the preparation of pharmaceutical compositions
GB9420172D0 (en) 1994-10-06 1994-11-23 Boots Co Plc Therapeutic agents
GB9420168D0 (en) 1994-10-06 1994-11-23 Boots Co Plc Therapeutic agents
WO1996013510A1 (en) 1994-10-28 1996-05-09 Procept, Inc. Ruthenium complexes and their use as immunosuppressive agents
US5512687A (en) 1994-10-28 1996-04-30 Procept, Inc. Compounds for inhibiting immune response
DE69530616T2 (en) 1994-11-10 2004-04-01 Pfizer Inc. MACROCYCLIC LACTON COMPOUNDS AND METHOD FOR THE PRODUCTION THEREOF
IT1270694B (en) 1994-11-15 1997-05-07 Italfarmaco Spa FLUORENYL-HYDROXAMIC DERIVATIVES FOR IMMUNOSOPPRESSIVE AND ANTI-INFLAMMATORY ACTIVITIES
US5491231A (en) 1994-11-28 1996-02-13 American Home Products Corporation Hindered N-oxide esters of rapamycin
US5563145A (en) 1994-12-07 1996-10-08 American Home Products Corporation Rapamycin 42-oximes and hydroxylamines
CZ172497A3 (en) 1994-12-07 1997-10-15 Hoffmann La Roche Fragments of monoclonal substance exhibiting immunosuppressor activity
US5482936A (en) 1995-01-12 1996-01-09 Minnesota Mining And Manufacturing Company Imidazo[4,5-C]quinoline amines
WO1996024579A1 (en) 1995-02-10 1996-08-15 Fournier Industrie Et Sante 15-deoxyspergualin analogs, therapeutical use thereof, and method for preparing same
US5670504A (en) 1995-02-23 1997-09-23 Merck & Co. Inc. 2,6-diaryl pyridazinones with immunosuppressant activity
US5496832A (en) 1995-03-09 1996-03-05 American Home Products Corporation Method of treating cardiac inflammatory disease
IL117483A (en) 1995-03-17 2008-03-20 Bernard Brodeur Proteinase k resistant surface protein of neisseria meningitidis
WO1996030381A1 (en) 1995-03-28 1996-10-03 Novo Nordisk A/S Immunosuppressive agents
JPH08333390A (en) 1995-04-07 1996-12-17 Hoechst Japan Ltd Peptide and therapeutic agent for autoimmune disease comprising the same
US5631282A (en) 1995-06-07 1997-05-20 Merck & Co., Inc. Triterpenes
IL118544A (en) 1995-06-07 2001-08-08 Smithkline Beecham Corp Imidazole derivatives, process for their preparation and pharmaceutical compositions comprising them
NZ311647A (en) 1995-06-09 1999-11-29 Novartis Ag Rapamycin derivatives
GB9513261D0 (en) 1995-06-29 1995-09-06 Smithkline Beecham Biolog Vaccines
AR006514A1 (en) 1995-07-04 1999-09-08 Sandoz Ag A MACROLID, ITS USES, A PROCESS TO PRODUCE IT, A BIOLOGICALLY PURE ISOLATE CAPABLE OF PRODUCING IT, AND A PHARMACEUTICAL COMPOSITION THAT IT INCLUDES
JP3195364B2 (en) 1995-07-13 2001-08-06 アノーメッド インコーポレイティド N, N-dimethyl-8,8-dipropyl-2-azaspiro [4.5] decane-2-propanamine dimaleate
AU6657596A (en) 1995-07-31 1997-02-26 Ciba-Geigy Ag Trindene compounds
AU6733996A (en) 1995-07-31 1997-02-26 Ciba-Geigy Ag Staurosporine analogues
JPH11512096A (en) 1995-08-24 1999-10-19 メルク エンド カンパニー インコーポレーテッド Method for producing imidazolyl macrolide immunosuppressant
US5777105A (en) 1995-08-24 1998-07-07 Merck & Co., Inc. Process for the preparation of imidazolyl macrolide immunosuppressants
WO1997009325A1 (en) 1995-09-01 1997-03-13 Signal Pharmaceuticals, Inc. Pyrimidine carboxylates and related compounds and methods for treating inflammatory conditions
EP0850228A1 (en) 1995-09-01 1998-07-01 Signal Pharmaceuticals, Inc. Pyrimidine carboxamides and related compounds and methods for treating inflammatory conditions
GB9518417D0 (en) 1995-09-08 1995-11-08 Fujisawa Pharmaceutical Co Novel compound
EP0852233A4 (en) 1995-09-21 1999-09-15 Nippon Shinyaku Co Ltd Cyclosporin phosphate derivatives and medicinal composition
GB9520363D0 (en) 1995-10-05 1995-12-06 Chiroscience Ltd Compounds
GB9520364D0 (en) 1995-10-05 1995-12-06 Chiroscience Ltd Compouundds
DE19538402A1 (en) 1995-10-14 1997-04-17 Boehringer Mannheim Gmbh Lipid alcohols as new immunosuppressive and antiviral drugs
DE19540475A1 (en) 1995-10-20 1997-04-24 Schering Ag Chiral methylphenyloxazolidinones
AU708667B2 (en) 1995-10-31 1999-08-12 Merck & Co., Inc. Triterpene derivatives with immunosuppressant activity
US5679705A (en) 1995-10-31 1997-10-21 Merck & Co., Inc. Triterpene derivatives with immunosuppressant activity
EP0877554A1 (en) 1995-10-31 1998-11-18 Merck & Co., Inc. Triterpene derivatives with immunosuppressant activity
WO1997016438A1 (en) 1995-10-31 1997-05-09 Merck & Co., Inc. Triterpene derivatives with immunosuppressant activity
US5696156A (en) 1995-10-31 1997-12-09 Merck & Co. Inc. Triterpene derivatives with immunosuppressant activity
AU707991B2 (en) 1995-10-31 1999-07-29 Merck & Co., Inc. Triterpene derivatives with immunosuppressant activity
US5874411A (en) 1995-11-13 1999-02-23 Glycomed Incorporated Oligosaccharide glycosides having mammalian immunosuppresive and tolerogenic properties
BR9607708A (en) 1995-12-01 1998-01-13 Kyowa Hakko Kogyo Kk Propenone derivative
GB9524812D0 (en) 1995-12-05 1996-02-07 Leo Pharm Prod Ltd Chemical compounds
GB9526208D0 (en) 1995-12-21 1996-02-21 Res Inst Medicine Chem Chemical compounds
AU1812897A (en) 1996-03-04 1997-09-22 Taisho Pharmaceutical Co., Ltd. Pyrrolidone derivatives
GB9606452D0 (en) 1996-03-27 1996-06-05 Sandoz Ltd Organic compounds
JP2000511769A (en) 1996-04-02 2000-09-12 スミスクライン・ビーチャム・コーポレイション New compound
FR2747680B1 (en) 1996-04-18 1998-07-03 Roussel Uclaf NOVEL STEROIDS, THEIR APPLICATION AS MEDICAMENTS, THEIR PREPARATION PROCESS, THE INTERMEDIATES THEREOF AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
ATE199083T1 (en) 1996-04-22 2001-02-15 Shionogi & Co TERPHENYL COMPOUNDS AND MEDICINAL PRODUCTS CONTAINING THEM
IL126674A (en) 1996-04-23 2005-08-31 Vertex Pharma Use of cyclic and heterocyclic compounds for preparing pharmaceutical compositions inhibiting impdh activity, pharmaceutical compositions containing the same and novel thiazole and oxazole urea derivatives
DE19616509A1 (en) 1996-04-25 1998-01-15 Asta Medica Ag New specific immunophilin ligands as anti-asthmatics, immunosuppressants
AUPN952696A0 (en) 1996-04-29 1996-05-23 Fujisawa Pharmaceutical Co., Ltd. New heterocyclic compounds
WO1997043303A1 (en) 1996-05-14 1997-11-20 Smithkline Beecham Corporation Novel compounds
JP3851661B2 (en) 1996-05-14 2006-11-29 第一製薬株式会社 Novel physiologically active substance and method for producing the same
IT1283637B1 (en) 1996-05-14 1998-04-23 Italfarmaco Spa COMPOUNDS WITH ANTI-INFLAMMATORY AND IMMUNOSOPPRESSIVE ACTIVITY
US6436903B1 (en) 1996-05-22 2002-08-20 Stanford University (Board Of Trustees Of The Leland Standford Junior University) Immunomodulating compounds comprising d-isomers of amino acids
WO1997044351A1 (en) 1996-05-24 1997-11-27 The Board Of Trustees Of Leland Stanford Junior University Immunomodulating dimers
US5739169A (en) 1996-05-31 1998-04-14 Procept, Incorporated Aromatic compounds for inhibiting immune response
GB9611603D0 (en) 1996-06-04 1996-08-07 Leo Pharm Prod Ltd Chemical compounds
DE69719320T2 (en) 1996-06-11 2003-12-11 Novartis Ag, Basel COMBINATION OF A SOMATOSTATIN ANALOG AND A RAPAMYCIN
DE19624704A1 (en) 1996-06-20 1998-01-08 Klinge Co Chem Pharm Fab New pyridylalkanoic acid amides
DE19624659A1 (en) 1996-06-20 1998-01-08 Klinge Co Chem Pharm Fab New pyridylalkene and pyridylalkanoic acid amides
EP0907362A4 (en) 1996-06-27 1999-12-01 Smithkline Beecham Corp Il-8 receptor antagonists
DE19630390A1 (en) 1996-07-26 1998-01-29 Chiron Behring Gmbh & Co Proteins, in particular membrane proteins from Helicobacter pylori, their production and use
US6083986A (en) 1996-07-26 2000-07-04 Icagen, Inc. Potassium channel inhibitors
DK0956034T3 (en) 1996-07-30 2002-12-16 Novartis Ag Pharmaceutical compositions for the treatment of graft rejection, autoimmune or inflammatory conditions comprising cyclosporin A and 40-O- (2-hydroxyethyl) -rapamycin
US5877184A (en) 1996-08-06 1999-03-02 Merck & Co., Inc. Macrolides having immunosuppressive activity
US6093723A (en) 1996-08-09 2000-07-25 Boehringer Ingelheim Pharmaceuticals, Inc. 4-substituted beta-carbolines and analogs thereof
CA2264496C (en) 1996-09-04 2008-10-07 Takara Shuzo Co., Ltd. Fungal antigens and process for producing the same
DE19636150A1 (en) 1996-09-06 1998-03-12 Asta Medica Ag N-substituted indole-3-glyoxylamides with antiasthmatic, antiallergic and immunosuppressive / immunomodulating effects
JP2001500126A (en) 1996-09-09 2001-01-09 アメリカン・ホーム・プロダクツ・コーポレイション Alkylated rapamycin derivative
WO1998009972A1 (en) 1996-09-09 1998-03-12 American Home Products Corporation Rapamycin derivatives with unnatural stereochemistries
US6610661B1 (en) 1996-10-11 2003-08-26 The Regents Of The University Of California Immunostimulatory polynucleotide/immunomodulatory molecule conjugates
AU4822597A (en) 1996-10-16 1998-05-11 Merck & Co., Inc. Triterpene derivatives with immunosuppressant activity
AU4981397A (en) 1996-10-16 1998-05-11 Merck & Co., Inc. Triterpene derivatives with immunosupressant activity
WO1998016518A1 (en) 1996-10-16 1998-04-23 Merck & Co., Inc. Triterpene derivatives with immunosuppressant activity
CN1211244A (en) 1996-10-25 1999-03-17 协和发酵工业株式会社 Radicicol derivatives
CA2270373A1 (en) 1996-10-31 1998-05-07 American Home Products Corporation Synergistic composition comprising rapamycin and calcitriol
ES2277362T5 (en) 1996-10-31 2014-12-18 Human Genome Sciences, Inc. Streptococcus pneumoniae antigens and vaccines
GB9625271D0 (en) 1996-12-04 1997-01-22 Leo Pharm Prod Ltd Chemical compounds
GB9626643D0 (en) 1996-12-21 1997-02-12 Astra Pharma Prod Compounds
DE69822449T2 (en) 1997-01-21 2005-01-27 Smithkline Beecham Corp. NEW CANNABINOID RECEPTOR MODULATORS
WO1998032750A1 (en) 1997-01-23 1998-07-30 Kyowa Hakko Kogyo Co., Ltd. Ms-444 derivatives
US6406705B1 (en) 1997-03-10 2002-06-18 University Of Iowa Research Foundation Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
GB9705035D0 (en) 1997-03-11 1997-04-30 Pharmacia & Upjohn Spa Indolyl-pyrrolydenemethylpyrrole derivatives and process for their preparation
US6299881B1 (en) 1997-03-24 2001-10-09 Henry M. Jackson Foundation For The Advancement Of Military Medicine Uronium salts for activating hydroxyls, carboxyls, and polysaccharides, and conjugate vaccines, immunogens, and other useful immunological reagents produced using uronium salts
NZ500713A (en) 1997-04-04 2000-07-28 Yoshitomi Pharmaceutical 2-aminopropane-1,3-diol compounds and medicinal use thereof
EE9900528A (en) 1997-05-17 2000-06-15 Biogen, Incorporated Use of CD40: CD154 Binding Disruptor to Prevent Adaptive Immune Responses, especially Transplant Graft Rejection
AU741209B2 (en) 1997-05-23 2001-11-22 Aventisub Ii Inc. Novel triptolide derivatives useful in the treatment of autoimmune diseases
CN1257507A (en) 1997-05-23 2000-06-21 赫斯特·马里昂·罗素公司 Novel triptolide derivatives useful in the treatment of autoimmune diseases
ES2326848T3 (en) 1997-06-06 2009-10-20 The Regents Of The University Of California INHIBITORS OF DNA IMMUNOSTIMULATORY SEQUENCE ACTIVITY.
AU7553198A (en) 1997-06-12 1998-12-30 Sumitomo Pharmaceuticals Company, Limited Pyrazole derivatives
GB9712347D0 (en) 1997-06-14 1997-08-13 Smithkline Beecham Biolog Vaccine
GB9713156D0 (en) 1997-06-20 1997-08-27 Microbiological Res Authority Vaccines
WO1999000143A1 (en) 1997-06-27 1999-01-07 Biogen, Inc. Cd154 blockade therapy for autoimmune diseases
US6800744B1 (en) 1997-07-02 2004-10-05 Genome Therapeutics Corporation Nucleic acid and amino acid sequences relating to Streptococcus pneumoniae for diagnostics and therapeutics
US5948413A (en) 1997-07-17 1999-09-07 Board Of Trustees Operating Michigan State University Method and vaccine for treatment of pythiosis insidiosi in humans and lower animals
DE69815692T2 (en) 1997-09-05 2004-04-29 Glaxosmithkline Biologicals S.A. OIL IN WATER EMULSIONS WITH SAPONINES
JP4091250B2 (en) 1997-09-11 2008-05-28 タカラバイオ株式会社 Sphingosine derivatives and pharmaceutical composition
DE19742263A1 (en) 1997-09-25 1999-04-01 Asta Medica Ag New specific immunophilin ligands as anti-asthmatic, anti-allergic, anti-rheumatic, immunosuppressive, anti-psoriatic, neuroprotective
TW557297B (en) 1997-09-26 2003-10-11 Abbott Lab Rapamycin analogs having immunomodulatory activity, and pharmaceutical compositions containing same
US6756361B1 (en) 1997-10-14 2004-06-29 Nabi Enterococcus antigens and vaccines
AU1082399A (en) 1997-10-17 1999-05-10 Merck & Co., Inc. Furanyl, tetracyclic triterpene derivatives with immunosuppressant activity
AU1082999A (en) 1997-10-17 1999-05-10 Merck & Co., Inc. Tetracyclic triterpene derivatives with immunosuppressant activity
CA2308606A1 (en) 1997-11-06 1999-05-20 Chiron S.P.A. Neisserial antigens
AU1399199A (en) 1997-11-14 1999-06-07 Merck & Co., Inc. Immunosuppressant tetracyclic triterpenes
CN100390283C (en) 1997-11-21 2008-05-28 根瑟特公司 i(Chlanydia pneumoniae) genomic sequence and polypeptides, fragments thereof and uses thereof, in particular for the diagnosis, prevention and treatment of infection
EP2228384A1 (en) 1997-11-28 2010-09-15 Merck Serono Biodevelopment Chlamydia trachomatis genomic sequence and polypeptides, fragments thereof and uses thereof, in particular for the diagnosis, prevention and treatment of infection
BR9813373A (en) 1997-12-05 2000-10-03 Astrazeneca Uk Ltd Compound, process for preparing it, pharmaceutical composition, process for preparing it, use of a compound, and, processes for effecting immunosuppression and for treating or reducing the risk of reversibly obstructive airway disease in a patient
UA67760C2 (en) 1997-12-11 2004-07-15 Міннесота Майнінг Енд Мануфакчурінг Компані Imidazonaphthyridines and use thereof to induce the biosynthesis of cytokines
DE19756212A1 (en) 1997-12-17 1999-07-01 Klinge Co Chem Pharm Fab New cyclic imide-substituted pyridylalkane, alkene and alkyarboxylic acid amides
DE19756261A1 (en) 1997-12-17 1999-07-01 Klinge Co Chem Pharm Fab New aryl-substituted pyridylalkane, alkene and alkyarboxylic acid amides
DE19756235A1 (en) 1997-12-17 1999-07-01 Klinge Co Chem Pharm Fab New piperidinyl-substituted pyridylalkane alkene and alkane carboxylic acid amides
DE19756236A1 (en) 1997-12-17 1999-07-01 Klinge Co Chem Pharm Fab Novel piperazinyl-substituted pyridylalkane, alkene and alkyarboxylic acid amides
AU1719499A (en) 1997-12-18 1999-07-05 Boehringer Ingelheim Pharmaceuticals, Inc. Pyridones as src family sh2 domain inhibitors
JP2001526241A (en) 1997-12-19 2001-12-18 イミュネックス・コーポレーション Methods for reducing susceptibility to HIV infection
PT1047784E (en) 1998-01-14 2009-12-21 Novartis Vaccines & Diagnostic Neissera meningitidis antigens
CA2318779C (en) 1998-01-22 2009-08-25 Luminex Corporation Microparticles with multiple fluorescent signals
US6562817B1 (en) 1998-01-28 2003-05-13 Shionogi & Co., Ltd. Tricyclic compound
GB9802745D0 (en) 1998-02-09 1998-04-08 Pharmacia & Upjohn Spa Benzyloxy prodigiosine compounds
AU2832399A (en) 1998-02-10 1999-08-30 Novartis Ag B cell inhibitors
CA2318959A1 (en) 1998-02-20 1999-08-26 Avmax, Inc. Epimorphian compound and its use
US6303114B1 (en) 1998-03-05 2001-10-16 The Medical College Of Ohio IL-12 enhancement of immune responses to T-independent antigens
US6001651A (en) 1998-03-20 1999-12-14 Isis Pharmaceuticals Inc. Antisense modulation of LFA-3
GB9807721D0 (en) 1998-04-08 1998-06-10 Chiron Spa Antigen
CA2325939A1 (en) 1998-04-09 1999-10-21 Martin Friede Vaccine
WO1999055689A1 (en) 1998-04-24 1999-11-04 Kyowa Hakko Kogyo Co., Ltd. Radicicol derivatives
US5905090A (en) 1998-04-29 1999-05-18 Italfarmaco S.P.A. Analogues of the active metabolite of leflunomide
MXPA00010722A (en) 1998-05-01 2004-12-03 Chiron Corp Neisseria meningitidis antigens and compositions.
GB9810193D0 (en) 1998-05-12 1998-07-08 Smithkline Beecham Biolog Novel compounds
US6686450B1 (en) 1998-06-18 2004-02-03 Massachusetts Institute Of Technology Immunosuppressive agents that inhibit calcineurin function and uses of these agents
PA8474101A1 (en) 1998-06-19 2000-09-29 Pfizer Prod Inc PYROLEUM [2,3-D] PIRIMIDINE COMPOUNDS
HUP0102574A3 (en) 1998-06-19 2002-01-28 Pfizer Prod Inc Pyrrolo[2,3-d]pyrimidine compounds
GB9814844D0 (en) 1998-07-08 1998-09-09 Xenova Ltd Cytokine production inhibitors
ES2232147T3 (en) 1998-07-10 2005-05-16 Kyowa Hakko Kogyo Co., Ltd. DERIVATIVES OF LK6-A.
DK1105395T3 (en) 1998-08-17 2002-10-14 Wyeth Corp Photoregulated rapamycins
US6015809A (en) 1998-08-17 2000-01-18 American Home Products Corporation Photocyclized rapamycin
WO2000012122A2 (en) * 1998-08-27 2000-03-09 Universitätsklinikum Freiburg Low-molecular fragments of hyaluronic acid for the preparation of vaccines
ES2211161T3 (en) 1998-08-28 2004-07-01 Astrazeneca Ab I HAVE (2,3-D) NOVEDOUS PYRIMIDINDIONAS, PROCEDURE FOR THE PREPARATION AND USE OF THEM IN THERAPY.
US6548537B1 (en) 1998-09-02 2003-04-15 Pharmagenesis, Inc. Triptolide prodrugs having high aqueous solubility
GB9819898D0 (en) 1998-09-11 1998-11-04 Smithkline Beecham Plc New vaccine and method of use
AU5648699A (en) 1998-09-11 2000-04-03 Kyorin Pharmaceutical Co. Ltd. Malonic diester derivatives and process for producing the same
WO2000015645A1 (en) 1998-09-11 2000-03-23 Kyorin Pharmaceutical Co., Ltd. Phosphonic ester derivatives and process for producing the same
EP1032574B1 (en) 1998-09-30 2007-06-13 Walter Reed Army Institute of Research INDOLO 2,1-b|QUINAZOLE-6,12-DIONE ANTIMALARIAL COMPOUNDS AND METHODS OF TREATING MALARIA THEREWITH
BR9914374A (en) 1998-10-09 2002-09-17 Chiron Corp Genetic sequences of neisseria and methods for its use
HK1041483B (en) 1998-10-23 2004-12-24 霍夫曼-拉罗奇有限公司 Bicyclic nitrogen heterocycle
JP2002528499A (en) 1998-10-29 2002-09-03 ブリストル−マイヤーズ スクイブ カンパニー Amino nucleus-derived compounds that are inhibitors of the IMPDH enzyme
US6303637B1 (en) 1998-10-30 2001-10-16 Merck & Co., Inc. Heterocyclic potassium channel inhibitors
JP2002529069A (en) 1998-11-12 2002-09-10 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア Chlamydia pneumoniae genome sequence
AU1411700A (en) 1998-12-01 2000-06-19 Sankyo Company Limited Macrolide compounds and method for evaluating immunosuppressants
CN1177831C (en) 1998-12-04 2004-12-01 神经研究公司 Novel benzimidazolone-, benzoxazolone- or benzothiazolinone derivatives as ion channel modulators
AU1549700A (en) 1998-12-04 2000-06-26 Neurosearch A/S Ion channel modulating agents
US6399578B1 (en) 1998-12-09 2002-06-04 La Jolla Pharmaceutical Company Conjugates comprising galactose α1,3 galactosyl epitopes and methods of using same
AU2173500A (en) 1998-12-09 2000-06-26 La Jolla Pharmaceutical Company Methods and formulations for reducing circulating antibodies
GB9828000D0 (en) 1998-12-18 1999-02-10 Chiron Spa Antigens
WO2000039129A1 (en) 1998-12-28 2000-07-06 K.U. Leuven Research & Development Immunosuppressive effects of pteridine derivatives
US6110922A (en) 1998-12-29 2000-08-29 Abbott Laboratories Cell adhesion-inhibiting antiinflammatory and immune-suppressive compounds
JP2000256323A (en) 1999-01-08 2000-09-19 Japan Tobacco Inc 2-oxoquinoline compound and its medicinal use
CZ20012919A3 (en) 1999-02-10 2002-03-13 Sankyo Company, Limited Ether type lipid A1-carboxylic acid analogues
CO5140104A1 (en) 1999-02-16 2002-03-22 Novartis Ag MEVINOLINE DERIVATIVES AND PHARMACEUTICAL PREPARATION CONTAINING THEM
CN1155391C (en) 1999-03-11 2004-06-30 东洋水产株式会社 novel immunosuppressant
KR100642044B1 (en) 1999-03-19 2006-11-10 글락소스미스클라인 바이오로지칼즈 에스.에이. vaccine
CN1196687C (en) 1999-03-19 2005-04-13 沃泰克斯药物股份有限公司 Inhibitors of IMPDH enzyme
EP1165575A1 (en) 1999-03-31 2002-01-02 Abbott Laboratories Phosphate containing macrocyclic immunomodulators
US6121257A (en) 1999-03-31 2000-09-19 Abbott Laboratories Sulfamate containing macrocyclic immunomodulators
UA74781C2 (en) 1999-04-02 2006-02-15 Abbott Lab Antiinflammatory and immumosuppressive compounds inhibiting cell adhesion
PL215901B1 (en) 1999-04-15 2014-02-28 Bristol Myers Squibb Co Cyclic protein tyrosine kinase inhibitors
IT1312083B1 (en) 1999-04-20 2002-04-04 Smithkline Beecham Spa MORPHINOID DERIVATIVES, PROCEDURE FOR THEIR PREPARATION AND THERAPEUTIC USE.
WO2000067161A2 (en) 1999-05-04 2000-11-09 Grant Lee H Method and apparatus for categorizing and retrieving network pages and sites
US6051590A (en) 1999-05-13 2000-04-18 Merck & Co., Inc. Immunosuppressant tricyclic compounds
FR2794742B1 (en) 1999-06-11 2005-06-03 Sanofi Synthelabo NOVEL BENZENE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME
CN1372548A (en) 1999-07-01 2002-10-02 味之素株式会社 Heterocyclic compounds and their medicinal uses
WO2001005750A1 (en) 1999-07-19 2001-01-25 Shionogi & Co., Ltd. p-TERPHENYL COMPOUNDS BEARING ACYLOXYMETHOXYCARBONYL SIDE CHAINS
CN1361766A (en) 1999-07-19 2002-07-31 盐野义制药株式会社 Tricyclic compounds with acyloxymethoxycarbonyl side chains
AU6016000A (en) 1999-07-23 2001-02-13 Shionogi & Co., Ltd. Tricyclic compounds and drug compositions containing the same
WO2001008636A2 (en) 1999-08-03 2001-02-08 The Ohio State University Polypeptides and polynucleotides for enhancing immune reactivity to her-2 protein
US6331547B1 (en) 1999-08-18 2001-12-18 American Home Products Corporation Water soluble SDZ RAD esters
ATE247657T1 (en) 1999-09-17 2003-09-15 Basf Ag PYRAZOLOPYRIMIDINES AS MEDICINAL PRODUCTS
US6506769B2 (en) 1999-10-06 2003-01-14 Boehringer Ingelheim Pharmaceuticals, Inc. Heterocyclic compounds useful as inhibitors of tyrosine kinases
ES2225231T3 (en) 1999-10-06 2005-03-16 Boehringer Ingelheim Pharmaceuticals Inc. HETEROCICLICAL COMPOUNDS, USEFUL AS INHIBITORS OF THYROSINE KINASES.
US8273360B2 (en) 2000-01-17 2012-09-25 Novartis Ag Outer membrane vesicle (OMV) vaccine comprising N. meningitidis serogroup B outer membrane proteins
AT409085B (en) 2000-01-28 2002-05-27 Cistem Biotechnologies Gmbh PHARMACEUTICAL COMPOSITION FOR IMMUNULATING AND PRODUCING VACCINES
US20030045482A1 (en) * 2000-02-16 2003-03-06 Kenyon Keith E. Using D-ribose with or without anti-microbial agents to enhance healing and subsequent recovery by both synthesizing and sparing NAD derivatives
GB0012383D0 (en) 2000-05-22 2000-07-12 Novartis Ag Organic compounds
DE60118917T2 (en) 2000-06-26 2006-11-30 Pfizer Products Inc., Groton PYRROLO [2,3-d] PYRIMIDINE COMPOUNDS AS IMMUNOSUPPRESSIVE ACTIVE SUBSTANCES '
AU6871801A (en) 2000-06-29 2002-01-14 Abbott Lab Aryl phenylheterocyclyl sulfide derivatives and their use as cell adhesion-inhibiting anti-inflammatory and immune-suppressive agents
EP1297005B1 (en) 2000-07-03 2009-08-26 Novartis Vaccines and Diagnostics S.r.l. Immunisation against chlamydia pneumoniae
BR0112484A (en) 2000-07-13 2003-09-23 Sankyo Co Compound or a pharmaceutically acceptable salt, ester or other derivative thereof, pharmaceutical composition, use of a compound or a pharmaceutically acceptable salt or ester or other derivative thereof and process for the preparation thereof
AU8743001A (en) 2000-08-28 2002-03-13 Aventis Pasteur Moraxella polypeptides and corresponding dna fragments and uses thereof
AU8533101A (en) 2000-08-31 2002-03-13 Merck & Co Inc Phosphate derivatives as immunoregulatory agents
US6399626B1 (en) 2000-10-02 2002-06-04 Wyeth Hydroxyesters of 7-desmethylrapamycin
WO2002028862A2 (en) 2000-10-02 2002-04-11 Emory University Triptolide analogs for the treatment of autoimmune and inflammatory disorders
US6440991B1 (en) 2000-10-02 2002-08-27 Wyeth Ethers of 7-desmethlrapamycin
WO2002030938A1 (en) 2000-10-10 2002-04-18 Sankyo Company, Limited Benzhydryl derivatives
EP2284182A1 (en) 2000-10-27 2011-02-16 Novartis Vaccines and Diagnostics S.r.l. Nucleic acids and proteins from streptococcus groups A and B
US6887876B2 (en) 2000-12-14 2005-05-03 Ortho-Mcneil Pharmaceutical, Inc. Benzamidine derivatives
CA2433018A1 (en) 2000-12-21 2002-06-27 Joel C. Barrish Thiazolyl inhibitors of tec family tyrosine kinases
EP1344525A4 (en) 2000-12-22 2005-05-25 Ishihara Sangyo Kaisha Aniline derivatives or salts thereof and cytokine production inhibitors containing the same
JP2004269356A (en) 2000-12-27 2004-09-30 Ajinomoto Co Inc Adhesion preventing agent for wound part
KR20030070082A (en) 2000-12-28 2003-08-27 시오노기세이야쿠가부시키가이샤 Pyridone derivative having affinity for cannabinoid 2-type receptor
RU2281955C2 (en) 2001-01-02 2006-08-20 Астеллас Фарма Инк. Peptide compounds
JP4094955B2 (en) 2001-01-18 2008-06-04 塩野義製薬株式会社 Terphenyl compound having a substituted amino group
EP1354877A1 (en) 2001-01-22 2003-10-22 Shionogi & Co., Ltd. Hetero-tricyclic compounds having substituted amino groups
GB0103424D0 (en) 2001-02-12 2001-03-28 Chiron Spa Gonococcus proteins
US20030044406A1 (en) 2001-03-02 2003-03-06 Christine Dingivan Methods of preventing or treating inflammatory or autoimmune disorders by administering CD2 antagonists in combination with other prophylactic or therapeutic agents
EP1375489B1 (en) 2001-03-08 2008-08-20 Shionogi & Co., Ltd. Medicinal composition containing 1,3-thiazine derivative
CA2444278C (en) 2001-04-20 2011-11-22 Debiopharm S.A. Modified cyclosporine which can be used as a pro-drug and use thereof
ATE557041T1 (en) 2001-05-18 2012-05-15 Us Gov Health & Human Serv PEPTIDE VACCINES AGAINST GROUP A STREPTOCOCCE
NZ546711A (en) 2001-12-12 2008-06-30 Chiron Srl Immunisation against chlamydia trachomatis
GB0203403D0 (en) 2002-02-13 2002-04-03 Chiron Spa Chlamydia cytotoxic-T cell epitopes
GB0210128D0 (en) 2002-05-02 2002-06-12 Chiron Spa Nucleic acids and proteins from streptococcus groups A & B
US6914053B2 (en) * 2002-09-09 2005-07-05 Cv Therapeutics, Inc. Adenosine A3 receptor agonists
PT1551357E (en) 2002-09-13 2014-10-10 Novartis Vaccines & Diagnostic Group b streptococcus vaccine
WO2004087153A2 (en) * 2003-03-28 2004-10-14 Chiron Corporation Use of organic compounds for immunopotentiation
NZ543467A (en) 2003-04-10 2008-07-31 Novartis Vaccines & Diagnostic The severe acute respiratory syndrome coronavirus
MXPA05013260A (en) 2003-06-26 2006-03-09 Chiron Corp Immunogenic compositions for chlamydia trachomatis.
US7709009B2 (en) 2003-07-31 2010-05-04 Novartis Vaccines And Diagnostics, Srl Immunogenic compositions for streptococcus pyogenes
AU2004315509A1 (en) * 2003-12-05 2005-08-18 Becton, Dickinson And Company Methods of enhancing immune response in the intradermal compartment and compounds useful in the methods
US7592326B2 (en) * 2004-03-15 2009-09-22 Karaolis David K R Method for stimulating the immune, inflammatory or neuroprotective response

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4017608A (en) * 1973-12-14 1977-04-12 Strategic Medical Research Corporation Therapeutic composition and method of therapeutically treating warm blooded animals therewith
JP2004155777A (en) * 2002-10-16 2004-06-03 Asahi Kasei Pharma Kk Therapeutic agent for chronic hepatitis c
US20050037018A1 (en) * 2003-06-20 2005-02-17 Innogentics N.V. HCV combination therapy

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
BOSTON LIFE SCIENCES INC/DE: "BLSI Amended Annual Report (10-K/A)", EDGAR-ONLINE, 30 May 1996 (1996-05-30), pages 1 - 31, XP002419783, Retrieved from the Internet <URL:HTTP://sec.edgar-online.com/1996/05/30/00/0000950109-96-003494/Section2.asp> [retrieved on 20070209] *
DATABASE WPI Week 200440, Derwent World Patents Index; AN 2004-424369, XP002419800 *
PANCHEVA SONJA ET AL: "Potentiating effect of mizoribine on the anti-herpes virus activity of acyclovir.", ZEITSCHRIFT FUER NATURFORSCHUNG SECTION C JOURNAL OF BIOSCIENCES, vol. 57, no. 9-10, October 2002 (2002-10-01), pages 902 - 904, XP008074987, ISSN: 0939-5075 *
SHUTO, S.; HARAMUISHI, K.; FUKUOKA, M.; MATSUDA, A.: "Synthesis of sugar-modified analogs of bredinin (mizoribine), a clinically useful immunosuppressant, by a novel photochemical imidazole ring-cleavage reaction as the key step", J. CHEM. SOC., PERKIN TRANS. 1, vol. 21, 2000, pages 3603 - 3609, XP008074984 *
VILLALON M D G ET AL: "Activity of several S-adenosylhomocysteine hydrolase inhibitors against African swine fever virus replication in Vero cells", ANTIVIRAL RESEARCH 1993 NETHERLANDS, vol. 20, no. 2, 1993, pages 131 - 144, XP002419782, ISSN: 0166-3542 *

Also Published As

Publication number Publication date
EP1768662A2 (en) 2007-04-04
US20110104186A1 (en) 2011-05-05
CA2571710A1 (en) 2006-11-02
EP2583678A2 (en) 2013-04-24
EP2583678A3 (en) 2013-11-13
WO2006115509A2 (en) 2006-11-02

Similar Documents

Publication Publication Date Title
WO2004087153A3 (en) Use of organic compounds for immunopotentiation
WO2006115509A3 (en) Small molecule immunopotentiators and assays for their detection
WO2000062800A3 (en) Adjuvant composition comprising saponin and an immunostimulatory oligonucleotide
WO2006012527A8 (en) Bivalent linkers and conjugates thereof
WO2005120461A3 (en) Liposomal formulations comprising dihydrosphingomyelin and methods of use thereof
WO2006072625A8 (en) Anti-kir combination treatments and methods
WO2006031878A3 (en) Imidazoquinoline compounds
WO2005019258A3 (en) Compositions and methods for the treatment of immune related diseases
WO2004092360A3 (en) The severe acute respiratory syndrome coronavirus
WO2009060281A3 (en) Immune stimulatory oligoribonucleotide analogs containing modified oligophosphate moieties
WO2006131591A3 (en) An entacapone-containing oral dosage form
WO2008013954A3 (en) Tyrosine phosphorylation sites
WO2008054597A3 (en) Tyrosine phosphorylation sites
TWI367880B (en) Carbazole compounds
WO2005120558A3 (en) Methods for making compositions comprising heat shock proteins or alpha-2-macroglobulin for the treatment of cancer and infectious disease
EP1667716B8 (en) Cytotoxicity mediation of cells evidencing surface expression of cd44
WO2004098524A3 (en) Lipid platinum complexes and methods of use thereof
WO2007022511A3 (en) Listeria-induced immunorecruitment and activation, and methods of use thereof
WO2008013934A8 (en) Tyrosine phosphorylation sites
WO2007066336A3 (en) Chemical derivatives of jasmonate, pharmaceutical compositions and methods of use thereof
WO2003045324A3 (en) 14-methyl-epothilones
WO2005054172A3 (en) Jasmonate derivative compounds, pharmaceuticals compositions and methods of use thereof
WO2007062370A3 (en) Calcilytic compounds
WO2004081199A3 (en) Novel compositions and methods for the treatment of immune related disease
WO2007066337A3 (en) Jasmonate derivatives, pharmaceutical compositions and methods of use thereof

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2571710

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2007518321

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Country of ref document: DE

WWE Wipo information: entry into national phase

Ref document number: 2005857800

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2005857800

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 11630550

Country of ref document: US